All News
Ixekizumab Effective in Ankylosing Spondylitis
Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.
Read Article
NPF Dietary Recommendations for Psoriatic Disease
The National Psoriasis Foundation has released dietary recommendations for adults with psoriasis and psoriatic arthritis, based on a systematic review of the current literature, with the strongest focus on weight reduction for those who are overweight or obese.
Read Article
Five Barriers to Biosimilar Adoption in the US
A recent Deloitte analysis of the biosimilar market in the USA suggests there are defined obstacles to biosimilar use that must be dealt with, especially as the current administration is seeking to lower drug prices and reduce out-of-pocket costs for US consumers.
Read Article
Can DMARDs Delay Rheumatoid Onset?
Preclinical rheumatoid arthritis (RA) is a hot new area wherein at risk individuals (seropositive, first degree relatives of RA patients, etc.) are being studied to assess the triggers that lead to progression to RA or whether therapies can be used to avert the onset of RA.
Read Article
Enthesitis in PsA: A New Focus of Treatment?
Patients with psoriatic arthritis (PsA) whose disease manifestations include enthesitis showed significantly greater responses to interleukin (IL)-23 inhibition than to blocking tumor necrosis factor (TNF), suggesting the possibility that treatment decisions in the future might be guided by speci
Read Article
Abatacept Misses in Lupus Nephritis
Dr. Richard Furie, MD, of Northwell Health in New York, presented the findings ofa large phase III trial of abatacept (Orencia) in lupus nephritis showing the agent failed to achieve a complete renal response.
Read Article
The RheumNow Week in Review – EULAR18 Epilogue (6.22.18)
Dr. Jack Cush reviews EULAR 2018 and the past week's news and reports from RheumNow.com, including DMARDs in OA, the price of Penicillamine, Infections when ANCA+, CV outcomes in gout, NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes.
Read Article
Cosentyx Gets Radiographic Protection Indication for Psoriatic Arthritis
Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab) significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).
Read Article
EULAR 2018 - Day 4 Report
The EULAR 2018 wound down on Saturday with fewer oral presentations but many posters. In my last report I put together a collection of impressions and some thematic highlights not covered in previous reports.
Read Article
EULAR 2018 - Day 3 Report
Day 3 highlights include Behcet’s responds to apremilast and that biologics do not differentially affect TKR/THR post-operative infection rates. Be sure to check out today's podcast as well.
Read Article
High Biologic Blood Levels Increases the Risk of Infections in RA
A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs. While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.
Read Article
EULAR 2018 - Day 2 Report
Highlights from Day 2 of the EULAR meeting in Amsterdam include high MBDA scores in ACPA negative RA predicts remission; characterization of difficult RA; and gender differences in psoriatic responses to TNF inhibitors.
Read Article
Biosimilar Data at #EULAR2018
Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.
Abbvie Highlights Upadacitinib Trials at EULAR18
Abbvie press releases feature the results from 3 new trials to be presented during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderat
Read Article
EULAR 2018 - Day 1 Report
Highlights from the first day at EULAR include: canakinumab prevents acute gout; AS uveitis benefits from most TNFi; MRI does not improve T2Tor X-ray outcomes; baracitinib wins in SLE - maybe?; new lupus criteria; and lost survival in RA. Here's the RheumNow recap.
Read Article
Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)
Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.
Read Article
Vedolizumab Implicated in Exacerbations of SpA in IBD Patients
Beloved by gastroenterologist for treatment of inflammatory bowel disease (IBD), α4β7 integrin receptor vedolizumab (VDZ) has probably caught attention of many rheumatologist since the time it entered the market; largely for what it won't do for inflammatory arthritis.
Read Article
Risk of Psoriasis Complicating TNF Inhibitor Therapy
A population-based study of claims data from Korea shows that among inflammatory bowel disease (IBD) patients receiving tumour necrosis factor inhibitors (TNFi) there is a 3.7 per 100 patient-year risk of paradoxically developing psoriasis - a rate that is roughly 3-fold higher than risk in TNFi-naive IBD patients.
Read Article
The RheumNow Week in Review – Baricitinib Splash (6.7.18)
Dr. Jack Cush discusses the past week's news and journal articles featured on RheumNow.com - including reports on advance practice clinicians, baricitinib, gout, disease activity, hypomagnesemia and upadacitinib.
Read Article
FDA Approves Low Dose Baricitinib for Rheumatoid Arthritis
The US Food and Drug Administration has approved baricitinib (Olumiant) for use in adults in moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to TNF inhibitors (TNFi). It is not approved for use, nor has it been studied, in children.
Read Article
